Solasia Pharma K.K. Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-876	-1,961	-1,135	-2,492	-2,442
Depreciation & Amortization	37	195	500	534	495
Loss (Gain) From Sale of Assets	-	959	-	431	-
Loss (Gain) on Equity Investments	1	4	5	3	-
Other Operating Activities	10	-6	-36	-12	-2
Change in Accounts Receivable	-142	-164	540	-446	51
Change in Inventory	15	-5	-108	-14	4
Change in Accounts Payable	108	-92	-118	-65	-626
Change in Other Net Operating Assets	-	37	-7	-13	47
Operating Cash Flow	-847	-1,033	-359	-2,074	-2,473
Capital Expenditures	-	-1	-	-	-2
Cash Acquisitions	-	-	-	-14	-
Sale (Purchase) of Intangibles	-	-	-	-403	-161
Investment in Securities	-77	-	-	-	-
Other Investing Activities	-4	1	-	-1	-1
Investing Cash Flow	-81	-	-	-418	-164
Long-Term Debt Issued	-	500	-	500	-
Long-Term Debt Repaid	-32	-500	-	-500	-1,000
Net Debt Issued (Repaid)	-32	-	-	-	-1,000
Issuance of Common Stock	1,458	1,215	318	2,621	1,403
Other Financing Activities	-1	-35	-43	-50	-42
Financing Cash Flow	1,425	1,180	275	2,571	361
Foreign Exchange Rate Adjustments	5	11	7	10	25
Miscellaneous Cash Flow Adjustments	-	-1	1	-1	1
Net Cash Flow	502	157	-76	88	-2,250
Free Cash Flow	-847	-1,034	-359	-2,074	-2,475
Free Cash Flow Margin	-197.44%	-327.21%	-58.18%	-189.93%	-442.75%
Free Cash Flow Per Share	-3.57	-5.20	-2.13	-13.65	-19.02
Cash Interest Paid	1	1	-	1	1
Cash Income Tax Paid	-	1	25	28	22
Levered Free Cash Flow	-518.63	-1,252	62.13	-1,949	-1,667
Unlevered Free Cash Flow	-509.88	-1,249	62.13	-1,937	-1,653
Change in Working Capital	-19	-224	307	-538	-524

Source: S&P Global Market Intelligence. Standard template. Financial Sources.